FGFR1 and cancer: AZD4547 is an oral TKI selective for FGFR1, 2, and 3 which showed only a modest activity in patients with advanced cancer who harbor FGFR1, 2, or 3 alterations and enrolled in the arm of the National Cancer Institute—Molecular Analysis for Therapy Choice (NCT02465060) (71).